



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/724,613	11/28/2000	I. Lawrence Greenfield	7414.0022	7659
22852	7590 04/15/2004		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP			RILEY, JEZIA	
1300 I STREET, NW WASHINGTON, DC 20005			ART UNIT	PAPER NUMBER
			1637	
			DATE MAILED: 04/15/2004	•

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Action Comments	09/724,613 Examiner	GREENFIELD, I. LAWRENCE	
Office Action Summary		Art Unit	
The MAN INC DATE And the second	Jezia Riley	1637	
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet w	ith the correspondence address	
A SHORTENED STATUTORY PERIOD FOR FITHE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 Cafter SIX (6) MONTHS from the mailing date of this communicati - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ION. CFR 1.136(a). In no event, however, may a son. Gon. Gon.	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. 8 133)	
Status			
1) Responsive to communication(s) filed on	27 February 2004.		
2a)⊠ This action is FINAL . 2b)□	This action is non-final.		
3) Since this application is in condition for al	lowance except for formal matt	ers, prosecution as to the merits is	
closed in accordance with the practice un	der <i>Ex parte Quayle</i> , 1935 C.D). 11, 453 O.G. 213.	
Disposition of Claims			
4) Claim(s) <u>1-88 and 90-113</u> is/are pending	in the application.		
4a) Of the above claim(s) 26-87 is/are with	ndrawn from consideration.		
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>1,3-6,9-13,15,88,91-94,97-101 a</u>	· · · · · · · · · · · · · · · · · · ·		
7) Claim(s) <u>2,7,8,14,16-25,90,95,96,102 and</u>			
8) Claim(s) <u>1-88, 90-113</u> are subject to restri	iction and/or election requireme	ent.	
Application Papers			
9) The specification is objected to by the Exa	miner.		
10) The drawing(s) filed on is/are: a)		by the Examiner.	
Applicant may not request that any objection to			
Replacement drawing sheet(s) including the co		• •	
11) The oath or declaration is objected to by the			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for for	eign priority under 35 U.S.C. §	119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. Certified copies of the priority docur			
Certified copies of the priority docur	nents have been received in Ap	oplication No	

* See the attached detailed Office action for a list of the certified copies not received.

application from the International Bureau (PCT Rule 17.2(a)).

Attachment(s)	
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) Notice of Informal Patent Application (PTO-152)
Paper No(s)/Mail Date	6) Other:
S. Patent and Trademark Office	

3. Copies of the certified copies of the priority documents have been received in this National Stage

Application/Control Number: 09/724,613

Art Unit: 1637

1

DETAILED ACTION

Response to Remarks

1. Applicants' amendments, filed on 2/27/04, have been approved and entered. They have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Application/Control Number: 09/724,613

Art Unit: 1637

3. Claims 1, 3-6, 9-13, 15, 88, 91-94, 97-101, and 103 are rejected under 35 U.S.C. 102(e) as being anticipated by Lienau et al. (US 6,548,256).

Applicants amended the claims by adding to the preamble the phrase "whole tissue is not blood". Even though the preamble recites macerating a whole tissue wherein said whole tissue is not blood", the reference discloses the same composition in the context of isolating DNA from biological samples. Therefore since both the prior art and the instant application prepare and use composition which appeared to be identical, the reference inherently anticipate said instant invention, since that the instant specification discloses on page 8:

The term "biological sample" is used in a broad sense and is intended to include a variety of biological sources that contain nucleic acids. Such sources include, without limitation, whole tissues, including biopsy materials and aspirates; *in vitro* cultured cells, including primary and secondary cells, transformed cell lines, and tissue and cellular explants; whole blood, red blood cells, white blood cells, and lymph; body fluids such as urine, sputum, semen, secretions, eye washes and aspirates, lung washes and aspirates; and the like. Microorganisms and viruses that may be present on or in a biological sample are within the scope of the invention.

If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention's limitations, then the preamble is not considered a limitation and is of no significance to claim construction. Pitney Bowes, Inc.v. Hewlett-Packard Co., 182 F.3d 1298, 1305, 51 USPQ2d 1161, 1165 (Fed. Cir.1999). See also Rowe v. Dror, 112 F.3d 473, 478, 42

Application/Control Number: 09/724,613

Art Unit: 1637

USPQ2d 1550, 1553 (Fed. Cir.1997) ("where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation"); Kropa v. Robie, 187 F.2d at 152, 88 USPQ2d at 480-81(preamble is not a limitation where claim is directed to a product and the preamble merely recites a property inherent in an old product defined by the remainder of the claim); STX LLC. v. Brine, 211 F.3d 588, 591, 54 USPQ2d 1347, 1350 (Fed. Cir. 2000) (holding that the preamble phrase "which provides improved playing and handling characteristics" in a claim drawn to a head for a lacrosse stick was not a claim limitation).

- 4. Claims 2, 7, 8, 14, 16-25, 90, 95, 96, 102, 104-113 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 5. THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and

Art Unit: 1637

any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 571-272-0786. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Wednesday, April 14, 2004

JEZIA RILEY RIMARY EXAMINER